Monoclonal gammopathy of undetermined significance

Four Oral Presentations from the International Myeloma Foundation-Supported iStopMM Study to Take Center Stage at 2021 ASH Annual Meeting

Retrieved on: 
Thursday, November 4, 2021
Congress Center, Research, Prevalence, Quality of life, Diagnosis, University, Clinical study design, India Infoline, International Myeloma Foundation, Kidney, Black swan, IMF, SMM, Patient, Multiple myeloma, Foundation, Abstract, ASH, Risk, Board, Georgia World Congress Center, COVID-19, Education, Monoclonal gammopathy, Monoclonal gammopathy of undetermined significance, Pharmaceutical industry, Communications satellite

"It confirms that iStopMM really has the potential to profoundly impact the field of multiple myeloma."

Key Points: 
  • "It confirms that iStopMM really has the potential to profoundly impact the field of multiple myeloma."
  • Oral presentations at ASH 2021 from the iStopMM study:
    Screening for Monoclonal Gammopathy of Undetermined Significance: A Population-Based Randomized Clinical Trial.
  • First Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study (Abstract #156, Session: 652.
  • Prevalence of Smoldering Multiple Myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study (Abstract #151, Session: 652.

2021 Insights on Multiple Myeloma - Patients by Age Group and Gender - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 17, 2021
Health, Oncology, Multiple myeloma, Medical specialties, Medicine, Health care, Myeloma Canada, Monoclonal gammopathy of undetermined significance

The "Global Multiple Myeloma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Multiple Myeloma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • The research report, Global Multiple Myeloma Epidemiology and Patient Flow Analysis - 2021, provides Multiple Myeloma epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Multiple Myeloma patients, history of the disease at the population level (Multiple Myeloma prevalence, Multiple Myeloma incidence) and at the clinical level (from diagnosis to treated patients).
  • Demographics: Multiple Myeloma patients by age group, gender
    The data from this research will help executives:
    Establish basis for Multiple Myeloma market sizing, assessing market potential, and developing drug forecast models
    Identify Multiple Myeloma patients segments through age groups, gender, and disease sub-types
    Evaluate Multiple Myeloma market opportunities, identify target patient population
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210617005615/en/

Global Multiple Myeloma Treatment Market (2021 to 2026) - Key Drivers, Challenges and Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 11, 2021
Pharmaceutical, Health, Oncology, Medical specialties, Branches of biology, Medicine, Immune system, Multiple myeloma, Myeloma protein, Immunology, Plasma cell, Monoclonal gammopathy of undetermined significance, Smouldering myeloma

b'The "Multiple Myeloma Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com\'s offering.\nThis report offers strategic insights into the overall multiple myeloma treatment market along with the market size and estimates for the duration 2019 to 2029.

Key Points: 
  • b'The "Multiple Myeloma Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com\'s offering.\nThis report offers strategic insights into the overall multiple myeloma treatment market along with the market size and estimates for the duration 2019 to 2029.
  • The said research study cover in-depth analysis of multiple myeloma market segments based on type and different geographies further segmented by countries.
  • According to myeloma UK, in myeloma, plasma cells become abnormal, multiply uncontrollably and release only one type of antibody known as paraprotein, which has no useful function.
  • It is often through the measurement of this paraprotein that myeloma is diagnosed and monitored.\nFor the purpose of this study, the global multiple myeloma treatment market is segmented on the basis of type into Drug Therapy, Stem cell Transplantation, Biophosphonates, Radiation Therapy, & Surgical Therapy.

International Myeloma Working Group (IMWG) Will Honor Researchers Prof. Philippe Moreau, MD, and Dr. Sigurdur Kristinsson on June 12 at Annual Summit in Stockholm

Retrieved on: 
Wednesday, May 23, 2018
Health, International Myeloma Foundation, Non-profit organizations based in California, Medicine, Multiple myeloma, Norwalk, Connecticut, Myeloma Foundation, Monoclonal gammopathy of undetermined significance, Multiple Myeloma Research Foundation

"This prize is one of the most prestigious rewards that a physician working in the field of multiple myeloma may expect.

Key Points: 
  • "This prize is one of the most prestigious rewards that a physician working in the field of multiple myeloma may expect.
  • Durie Outstanding Achievement Award,which is named for IMF Chairman Dr. Brian Durie and recognizes excellence in myeloma research.
  • Dr. Kristinsson serves as principal investigator for Iceland Screens, Treats, or Prevents Multiple Myeloma ( iStopMM ), a population-based MGUS and multiple myeloma screening study.
  • Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest foundation focusing specifically on multiple myeloma.

NetVU and Vertafore Celebrate 40 Years of User Group Conference

Retrieved on: 
Wednesday, May 16, 2018
Economy, Insurance, Insurance industry, Monoclonal gammopathy of undetermined significance, Innovation

This year's annual user conference celebrates the 40th anniversary of the User Group Conference and unites agents, brokers, carriers, MGAs, and MGUs to learn about the latest industry trends and innovations.

Key Points: 
  • This year's annual user conference celebrates the 40th anniversary of the User Group Conference and unites agents, brokers, carriers, MGAs, and MGUs to learn about the latest industry trends and innovations.
  • "Insurance is all about relationships and our long-standing partnership with NetVU has created a world-class users group that is adapting and thriving in a rapidly changing industry," said Amy Zupon, CEO of Vertafore.
  • Each year, NetVU and Vertafore partner with a local charity in the location of the conference.
  • 2018 Vertafore and the Vertafore logo are registered trademarks of Vertafore.

Blood Cancer Precursor Found in 9/11 Firefighters

Retrieved on: 
Thursday, April 26, 2018
Medicine, Hematology, Monoclonal gammopathy of undetermined significance, Blood, Multiple myeloma, Immune system, Proteins, Oncology, Paraproteinemia, Plasma cell dyscrasia, Myeloma protein

We wanted to find early, predictive signs of cancer that would allow us to screen people and monitor those found to be at risk.

Key Points: 
  • We wanted to find early, predictive signs of cancer that would allow us to screen people and monitor those found to be at risk.
  • In MGUS (monoclonal gammopathy of undetermined significance), the blood's plasma cells produce an abnormal protein called monoclonal (M) protein that can be detected with blood tests.
  • MGUS generally causes no problems but can progress to multiple myeloma, a blood cancer diagnosed in about 30,000 Americans each year.
  • The MGUS study is titled "Multiple myeloma and its precursor disease among firefighters exposed to the World Trade Center disaster."